Luteolin-Fabricated ZnO Nanostructures Showed PLK-1 Mediated Anti-Breast Cancer Activity

Kollur, Shiva Prasad; Prasad, Shashanka K.; Pradeep, Sushma; Veerapur, Ravindra; Patil, Sharanagouda S.; Amachawadi, Raghavendra G.; S, Rajendra Prasad; Lamraoui, Ghada; Al‐Kheraif, Abdulaziz A.; Elgorban, Abdallah M.; Syed, Asad; Shivamallu, Chandan

doi:10.3390/biom11030385

Cited by 34 publications

(13 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…77 Shiva Prasad Kollur et al studied luteolin-fabricated ZnO nanostructures exhibiting PLK-1 mediated anti-breast cancer activity, which was superior to the activity exerted by each of the two components when tested individually. 78 International Journal of Nanomedicine 2023:18 Curcumin is an active ingredient of dietary spice that has various pharmacological properties including anticancer activity and has been used recently in breast cancer treatment. Curcumin conjugated with poly-glycerol-malic aciddodecanedioic acid (PGMD) NPs resulted in a formulation with increased anticancer activity compared to that of curcumin alone.…”

Section: Cancer Immunotherapy Using Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature

Yadav¹,

Puranik²,

Meshram³

et al. 2023

IJN

View full text Add to dashboard Cite

Cancer is a broad term for a group of diseases involving uncontrolled cell growth and proliferation. There is no cure for cancer despite recent significant improvements in screening, treatment, and prevention approaches. Among the available treatments, immunotherapy has been successful in targeting and killing cancer cells by stimulating or enhancing the body's immune system. Antibody-based immunotherapeutic agents that block immune checkpoint proteins expressed by cancer cells have shown promising results. The rapid development of nanotechnology has contributed to improving the effectiveness and reducing the adverse effects of these anti-cancer immunotherapeutic agents. Recently, engineered nanomaterials have been the focus of many state-of-The-art approaches toward effective cancer treatment. In this review, the contribution of various nanomaterials such as polymeric nanoparticles, dendrimers, microspheres, and carbon nanomaterials in improving the efficiency of anti-cancer immunotherapy is discussed as well as nanostructures applied to combination cancer immunotherapy.

show abstract

Section: Cancer Immunotherapy Using Nanoparticlesmentioning

confidence: 99%

Section: Cancer Immunotherapy Using Nanoparticlesmentioning

confidence: 99%

How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature

Yadav¹,

Puranik²,

Meshram³

et al. 2023

IJN

View full text Add to dashboard Cite

show abstract

“…They were then shade dried for 45 days at room temperature (28.5 °C). The dry components were then ground into a fine powder using a blender (Kollur et al, 2021).…”

Section: Plant Materials Collectionmentioning

confidence: 99%

Anticholinesterase activity of Areca Catechu: In Vitro and in silico green synthesis approach in search for therapeutic agents against Alzheimer’s disease

Pradeep

Prabhuswaminath

Reddy³

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

For many years, the primary focus has been on finding effective treatments for Alzheimer’s disease (AD), which has led to the identification of promising therapeutic targets. The necessity for AD stage-dependent optimal settings necessitated a herbal therapy strategy. The plant species Areca Catechu L. (AC) was selected based on the traditional uses against CNS-related diseases. AC leaf extract were prepared using a Soxhlet extraction method and hydroxyapatite nanoparticles (HAp-NPs) were synthesized from the same (AC-HAp-NPs). Powder X-ray diffractometer (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), selected area electron diffraction (SAED) and fourier transform infrared spectroscopy (FTIR) were used to confirm the structure and morphology of the as-prepared AC-HAp-NPs. The crystalline character of the AC-HAp-NPs was visible in the XRD pattern. The synthesized material was found to be nanoflake, with an average diameter of 15–20 nm, according to SEM analysis. The TEM and SAED pictures also revealed the form and size of AC-HAp-NPs. In vitro anti-acetylcholinesterase and butyrylcholinesterase (AChE and BChE) activities of hydroxyapatite nanoparticles produced from an AC leaf extract was tested in this study. When compared to control, AC-HAp-NPs had higher anti-AChE and BChE activity. The anti-acetylcholinesterase action of phytoconstituents generated from AC leaf extract was mediated by 4AQD and 4EY7, according to a mechanistic study conducted utilizing in silico research. The global and local descriptors, which are the underpinnings of Conceptual Density Functional Theory (CDFT), have been predicted through the MN12SX/Def2TZVP/H2O model chemistry to help in the comprehension of the chemical reactivity properties of the five ligands considered in this study. The CDFT experiments are supplemented by the calculation of several useful calculated pharmacokinetics indices, their expected biological targets connected to the bioavailability of the five ligands in order to further the goal of studying their bioactivity.

show abstract

“…High levels of PLK1 are restricted to actively dividing cells such as embryonic cells and hair follicles [ 11 ]. Elevated levels of PLK1 are also observed in different cancers, including NB, breast, colorectal, melanoma, prostate, ovarian, esophageal, and non-small-cell lung cancer [ 12 , 13 , 14 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth

2022

View full text Add to dashboard Cite

Polo-like kinase 1 (PLK1) is an essential cell cycle mitotic kinase component that plays an important role in cell cycle progression and has been reported to be involved in various cancers, including neuroblastoma (NB). PLK1 also regulates G2/M transition, chromosomal segregation, spindle assembly maturation, and mitotic exit. NB is an early embryonic-stage heterogeneous solid tumor and accounts for 15% of all pediatric cancer-related deaths. Therefore, we aimed to develop a targeting strategy for PLK1 by repurposing HMN-214 in NB. HMN-214 is a prodrug of HMN-176 and is known to selectively interfere with PLK1 function. In the present study, we performed the transcriptomic analysis of a large cohort of primary NB patient samples and revealed that PLK1 expression is inversely correlated with the overall survival of NB patients. Additionally, we found that PLK1 strongly correlates with NB disease and stage progression. HMN-214 significantly inhibited NB proliferation and colony formation in both MYCN-amplified and -nonamplified cell lines in a dose-dependent manner. Furthermore, HMN-214 induces apoptosis and significantly obstructs the cell cycle at the G2/M phase in NB cells by inhibiting multiple cell-cycle-related genes, such as PLK1, WEE1, CDK1, CDK2, Cyclin B1, CHK1, and CHK2. HMN-214 significantly inhibits cell cycle regulator CDK1 and the phosphorylation and activation of PLK1 in NB. In the NB 3D spheroid tumor model, HMN-214 significantly and in a dose-dependent manner inhibits spheroid tumor mass and growth. Overall, our study highlights that targeting PLK1 using HMN-214 is a novel therapeutic approach for NB.

show abstract

Luteolin-Fabricated ZnO Nanostructures Showed PLK-1 Mediated Anti-Breast Cancer Activity

Cited by 34 publications

References 58 publications

How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature

How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature

Anticholinesterase activity of Areca Catechu: In Vitro and in silico green synthesis approach in search for therapeutic agents against Alzheimer’s disease

Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth

Contact Info

Product

Resources

About